ArticleBMC infectious diseases2026
Symptom progression and viral shedding dynamics in children and adolescents with asymptomatic and mild COVID-19 infections.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveLimited research has examined the progression of disease symptoms and viral shedding dynamics using continuous daily cycle threshold (Ct) values in large pediatric populations infected with SARS-CoV-2.
methodsThis analysis included 7803 children and adolescents selected from a retrospective cohort of 174,371 individuals with COVID-19. Factors influencing symptom progression and viral shedding were evaluated across asymptomatic, asymptomatic-to-mild and mild symptom groups. Inverse Probability of Treatment Weighting (IPTW) was used to adjust for confounding and correct group imbalances.
resultsDuring follow-up, 86.2% of initially asymptomatic individuals progressed to mild disease. The median durations of hospital stay and viral shedding were both six days (interquartile range: 4–8 days). Older children (AOR: 1.13–1.53), females (AOR: 1.21), lower nadir N gene (AOR: 0.89) and vaccinated individuals (AOR by IPTW: 1.75–1.99) exhibited a higher likelihood of symptom progression. Older age (AHR: 1.13–1.44) and higher nadir N gene values (AHR: 1.15) were associated with an increased likelihood of viral shedding. Full vaccination demonstrated a modest association with viral shedding (AHR by IPTW: 1.08). Compared to the asymptomatic group, viral shedding was less likely in the asymptomatic-to-mild (AHR: 0.64) and mildly symptomatic (AHR: 0.60) groups.
conclusionIn pediatric COVID-19 patients, older age, female sex, lower nadir N gene and vaccination are associated with an increased likelihood of progression from asymptomatic to mild symptoms. Older age and higher nadir N gene correlate with a greater probability of viral shedding. Vaccination status is associated with a higher probability of symptomatic presentation and a weakly accelerated viral clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.